Efficacy and tolerability of vinorelbine in the cancer therapy

Current Drug Safety

Volumn 6, Issue 3, 2011, Pages 185-193

  Galano, Giuseppina ^a   Caputo, Mariella ^a   Tecce, Mario Felice ^a   Capasso, Anna ^a  

^a UNIVERSITY OF SALERNO   (Italy)

Author keywords

Antimitotic; Cancer; Efficacy; Tolerability; Vinorelbine

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); AMINO ACID; CALMODULIN; CAPECITABINE; CARBOPLATIN; CATHARANTHINE; CETUXIMAB; CISPLATIN; CYCLIC AMP; CYCLOPHOSPHAMIDE; DOCETAXEL; ETOPOSIDE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; GLUTATHIONE; IDARUBICIN; NAVELBINE; NAVELBINE ORAL; NERATINIB; PACLITAXEL; SATRAPLATIN; TRASTUZUMAB; TUBULIN; UFT; UNCLASSIFIED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; VINDOLINE;

ADVANCED CANCER; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BINDING AFFINITY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CELL RESPIRATION; CONSTIPATION; DIARRHEA; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG DOSAGE FORM; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TOLERABILITY; ENZYME ACTIVITY; EXTRAVASATION; FEBRILE NEUTROPENIA; GLUTATHIONE METABOLISM; GRANULOCYTOPENIA; HUMAN; INFECTION; INFLAMMATION; INJECTION SITE ERYTHEMA; INJECTION SITE IRRITATION; INJECTION SITE PAIN; INJECTION SITE WARMTH; LIPOGENESIS; LUNG NON SMALL CELL CANCER; METAPHASE; MICROTUBULE ASSEMBLY; MITOSIS INHIBITION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NUCLEIC ACID SYNTHESIS; OTOTOXICITY; PERIPHERAL NEUROPATHY; PHLEBITIS; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; SOLID TUMOR; TENDON REFLEX; THROMBOCYTOPENIA; TISSUE NECROSIS; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; HUMANS; MICROTUBULES; MITOSIS; NEOPLASMS; TUBULIN; VINBLASTINE;

EID: 80054107125     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488611797579302     Document Type: Review

References (31)

1. Hirsch J. An anniversary for cancer chemotherapy. JAMA 2006; 296 (12): 1518-20.
2. Joensuu H. Systemic chemotherapy for cancer: from weapon to treatment. Lancet Oncol 2008, 9 (3): 304.
3. Skeel RT. Handbook of Cancer Chemotherapy, Lippincott Williams & Wilkins 2003.
4. De Souza CP, Osmani SA. Mitosis, not just open or closed. Eukaryot Cell 2007; 6 (9): 1521-7.
5. Maton A, Hopkins, JJ, Susan LHD, Quon W, David W, Jill D. Cells: Building Blocks of Life. New Jersey: Prentice Hall. 1997, pp. 70-4.
6. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Mitosis. Molecular Biology of the Cell. Garland Science 2002.
7. Freeman S. Cell Division. Biological Science. Upper Saddle River, NJ: Prentice Hall., 2002; pp. 155-174.
8. Lodish H, Berk A, Zipursky L, Matsudaira P, Baltimore D, Darnell J. Overview Of The Cell Cycle And Its Control. Molecular Cell Biology W.H. Freeman 2000
9. McKnight JA, Principles of chemotherapy. Clin Tech Small Anim Pract 2003; 18 (2): 67-72.
10. Chabner B, Longo DL. Cancer Chemotherapy and Biotherapy: Principles and Practice. Philadelphia, Lippincott Willians & Wilkins, 2006.
11. Jordan MA, Thrower D, Wilson L. Mechanism of cell proliferation by Vinca alkaloids. Cancer Res 1991; 51: 2212-22.
12. Dhamodharan RI, Jordan MA, Thrower D, Wilson L, Wadsworth P. Vinblastine suppresses dynamics of individual microtubules in living cells. Mol Biol Cell 1995; 6: 1215-29.
13. Jordan MA, Himes RH, Wilson L. Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro. Cancer Res 1985; 45: 2741-7
14. Budman DR. Vinorelbine (Navelbine): A third-generation vinca alkaloid. Cancer Invest. 1997; 15: 475-90.
15. Kruczynski A, Barret JM, Etievant C, Colpaert F, Fahy J, Hill BT. Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid. Biochem. Pharmacol 1998; 55: 635-48.
16. Binet S, Chaineau E, Fellous A, et al. Immunofluorescence study of the action of navelbine, vincristine and vinblastine on mitotic and axonal microtubules. Int J Cancer 1990; 46: 262-6.
17. Ashizawa T, Miyoshi K, Asada M, Kobayashi E, Okabe M, Morimoto M, Gomi K, Hirata T. Anti-tumour activity of navelbine, a new vinca-alkaloid analog. Gan To Kagaku Ryoho 1993; 20: 59-66
18. Rahmani R, Bruno R, Iliadis A. Clinical pharmacokinetics of the antitumour drug Navelbine (5'noranhydrovinblastine). Cancer Res 1987; 43: 5796-9.
19. Zhou XJ, Boré P, Monjanel S. Pharmacokinetics of Navelbine after oral administration in cancer patients. Cancer Chemother Pharmacol. 1991; 29: 66-70.
20. Johnson SA, Harper P, Hortobagyi GN, Pouillart P. Vinorelbine: an overview. Cancer Treat Rev 1996; 22: 127-42.
21. Romero A, Rabinovich MG, Vallejo CT, Perez JE, Rodriguez R, Cuevas MA, Machiavelli M, Lacava JA, Langhi M, Romero Acuna L. Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol. 1994; 12: 336-41.
22. Cany L, Toulouse C, Ravaud A, Durand M, Mauriac L. Vinorelbine/5-FU combination in metastatic breast cancer chemotherapy: A retrospective study of 63 cases. Eur J Cancer. 1996; 32: 370-1
23. Ashizawa T, Miyoshi K, Asada M. Anti-tumour activity of navelbine, a new vinca-alkaloid analog. Gan To Kagaku Ryoho 1993; 20: 59-66.
24. Besenval M, Delgado M, Demarez JP, Krikorian A. Safety and tolerance of Navelbine in phase I-II clinical studies. Semin Oncol 1989; 16: 37-40.
25. ONS Clinical Practice Committe. Cancer Chemotherapy Guidelines and Recommendations for Practice. Pittsburgh, Pa: Oncology Nursing Society 1999; pp. 32-41.
26. Scott IL, Ralph JM., Voss ME, Vinorelbine Derivatives, United States Patent Application 2007/0179170 A1, 2007
27. Wolf MA, Guzzo PR., Scott IL, Vinorelbine Derivatives, United States Patent Application 2008/0125451 A1, 2008
28. Zacharchuk CM, Antineoplastic Combinations Containing HKI-272 and Vinorelbine, United States Patent Application 2009/0312360 A1, 2009
29. Zhang JA, Ahmad I. Vinorelbine compositions and methods of use, United States Patent Application 2004/0228911 A1, 2004
30. Bougaret J, Leverd E, Bohn MM, Heintz N, Oral pharmaceutical composition for soft capsules containing Vinorelbine and method of treatment. US7658943 (2010).
31. Paillard B, Avan JL, Bougaret J. Stable Pharmaceutical Composition of a Water-Soluble Vinorelbine Salt, United States Patent Application 2010/0196465, 2010.